Lv51
1148 积分 2022-02-15 加入
Systemic lupus erythematosus
26天前
已完结
Advances in the treatment of systemic lupus erythematosus
27天前
已完结
Optimization of CAR T-cell dose: a debated unresolved issue
1个月前
已完结
Novel strategies to manage CAR-T cell toxicity
1个月前
已完结
Designer lipids for delivering mRNA to the brain
1个月前
已完结
[China clinical practice guideline for stage Ⅳ primary lung cancer (2024 edition)]
3个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
3个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
5个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
5个月前
已完结
Randomized Phase I Trials — One Size Fits All?
6个月前
已完结
皖公网安备34019202002308
